- Home
- HPAI vs NVCT Comparison
HPAI vs NVCT Comparison
Compare HPAI & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPAI
- NVCT
- Stock Information
- Founded
- HPAI 2023
- NVCT 2020
- Country
- HPAI Singapore
- NVCT United States
- Employees
- HPAI N/A
- NVCT N/A
- Industry
- HPAI
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- HPAI
- NVCT Health Care
- Exchange
- HPAI NYSE
- NVCT Nasdaq
- Market Cap
- HPAI 221.3M
- NVCT 249.1M
- IPO Year
- HPAI N/A
- NVCT 2022
- Fundamental
- Price
- HPAI $5.00
- NVCT $8.98
- Analyst Decision
- HPAI
- NVCT Strong Buy
- Analyst Count
- HPAI 0
- NVCT 3
- Target Price
- HPAI N/A
- NVCT $17.00
- AVG Volume (30 Days)
- HPAI 8.2K
- NVCT 132.1K
- Earning Date
- HPAI 03-31-2025
- NVCT 05-06-2025
- Dividend Yield
- HPAI N/A
- NVCT N/A
- EPS Growth
- HPAI N/A
- NVCT N/A
- EPS
- HPAI 0.06
- NVCT N/A
- Revenue
- HPAI $31,475,664.00
- NVCT N/A
- Revenue This Year
- HPAI N/A
- NVCT N/A
- Revenue Next Year
- HPAI N/A
- NVCT N/A
- P/E Ratio
- HPAI $91.32
- NVCT N/A
- Revenue Growth
- HPAI 47.72
- NVCT N/A
- 52 Week Low
- HPAI $3.07
- NVCT $4.44
- 52 Week High
- HPAI $14.74
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- HPAI N/A
- NVCT 44.39
- Support Level
- HPAI N/A
- NVCT $9.92
- Resistance Level
- HPAI N/A
- NVCT $11.15
- Average True Range (ATR)
- HPAI 0.00
- NVCT 0.64
- MACD
- HPAI 0.00
- NVCT -0.09
- Stochastic Oscillator
- HPAI 0.00
- NVCT 26.94
About HPAI HELPORT AI LTD
Helport AI Ltd is a AI technology company based in Singapore dedicated to serving enterprises' customer contact centers with intelligent products, solutions, and a digital platform. Its software, Helport AI Assist (AI Assist), provides tailored AI-powered guidance and oversight for contact center interactions and customer experience, with functions including Agent Assistant, Quality Assurance (QA) Assistant, Supervisor Assistant, and Knowledge Base Assistant.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.